By HospiMedica International staff writers
Posted on 16 Jul 2020 
A new rapid diagnostic test for measuring levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells could serve as an ‘Immunity Passport’ for vaccine developers around the world as they begin larger Phase II and III clinical trials.


NeuCovix, a rapid 10-minute test unveiled by AXIM Biotechnologies, Inc. (San Diego, CA, USA), measures a specific subpopulation of antibodies to block binding of the virus to host cell receptors, unlike the currently available serological COVID-19 tests that detect an antibody response to the virus. While there are expensive, time consuming laboratory tests that measure neutralizing antibodies, NeuCovix differs in that it is a portable, low cost, rapid point-of-care test with results in 10 minutes.

Read the Full Article